European Pharma Sector and US Tariffs: Impact and Investment

Potential Impact of US Tariffs on European Pharma

• 💡 The European pharmaceutical sector is currently out of favor due to potential tariffs, alongside other factors.
• 📌 Identifying the most impacted companies is difficult due to complex and secretive supply chains.
• ⚠️ Novo Nordisk has been highlighted due to its manufacturing of active pharmaceutical ingredients for WGO in Denmark, though this may be due to greater transparency in their drug flows.

Carve-Outs and Lobbying Efforts

• 🎯 European companies are making significant announcements about manufacturing investments in the United States.
• 🤝 Companies are also working with the administration on most favored nation drug pricing policy.
• 🧩 It is speculated that a combination of tariffs and drug pricing policies could lead to a deal favorable to both the industry and the administration.

Sector-Specific Tariffs and Patient Impact

• ✅ The pharmaceutical sector has been carved out from country-specific tariffs, potentially explaining why the European healthcare index is outperforming.
• 🔬 Awaiting results from a Section 232 investigation for sector-specific tariffs, expected by the end of the month.
• ⚠️ Industry response suggests tariffs could negatively impact patients, potentially leading to drug shortages.

US Manufacturing Investments by European Pharma

• 🚀 Major large-cap European companies have announced extensive investments in the United States.
• 🇺🇸 AstraZeneca is reportedly considering changing its registration to the US, underscoring a commitment to US manufacturing.
• 💬 European-based companies are emphasizing their commitment to the US market and manufacturing operations.